- 米国企業
- Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.LYEL
| 2023年 12月31日 |
---|
Cash and cash equivalents | 146 |
---|
Marketable securities | 401 |
---|
Prepaid expenses and other current assets | 8 |
---|
Total current assets | 555 |
---|
Restricted cash | 0 |
---|
Marketable Securities, Noncurrent | 17 |
---|
Other investments | 32 |
---|
Property and equipment, net | 103 |
---|
Operating lease right-of-use assets | 40 |
---|
Other non-current assets | 4 |
---|
Total assets | 750 |
---|
Accounts payable | 5 |
---|
Accrued Liabilities and Other Liabilities | 28 |
---|
Success payment liabilities | 2 |
---|
Total current liabilities | 35 |
---|
Total current liabilities | 35 |
---|
Operating Lease, Liability, Noncurrent | 57 |
---|
Other non-current liabilities | 4 |
---|
Other non-current liabilities | 4 |
---|
Total liabilities | 95 |
---|
Total liabilities | 95 |
---|
Common Stock, Value, Issued | 0 |
---|
Additional paid-in capital | 1,657 |
---|
Accumulated other comprehensive loss | -0 |
---|
Accumulated deficit | -1,002 |
---|
Total stockholders’ equity | 655 |
---|
Common Stock, Value, Issued | 0 |
---|
Additional paid-in capital | 1,657 |
---|
Accumulated other comprehensive loss | -0 |
---|
Accumulated deficit | -1,002 |
---|
Total stockholders’ equity | 655 |
---|
Total liabilities and stockholders’ equity | 750 |
---|
Total liabilities and stockholders’ equity | 750 |
---|